FMP
CytoTools AG
T5O.DE
XETRA
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.
0.47 EUR
-0.026 (-5.53%)
About
ceo
Dr. Mark-André Freyberg
sector
Healthcare
industry
Biotechnology
website
https://cytotools.de
exchange
XETRA
Description
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urina...
CIK
N/A
ISIN
DE000A0KFRJ1
CUSIP
D1648F108
Address
Klappacher Strasse 126
Phone
49 6151 951 58
Country
DE
Employee
1
IPO Date
Dec 18, 2006
Summary
CIK
-
Exchange
XETRA
Industry
Biotechnology
Sector
Healthcare
CUSIP
D1648F108
ISIN
DE000A0KFRJ1
Country
DE
Price
0.47
Beta
1.2
Volume Avg.
1.35k
Market Cap
2.21M
Shares
-
52-Week
0.3-2.34
DCF
0.3
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.62
P/B
-
Website
https://cytotools.de
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest T5O.DE News
It looks like there's no news available.
